<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935126</url>
  </required_header>
  <id_info>
    <org_study_id>0352-2110</org_study_id>
    <nct_id>NCT03935126</nct_id>
  </id_info>
  <brief_title>Global Atrophie Biomarker Evaluation Study (GABiE)</brief_title>
  <acronym>GABiE</acronym>
  <official_title>A Biomarker Evaluation Study in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD) Evaluating the Use of Microperimetry (Fundus-controlled Perimetry) and Swept Source-OCT in Assessing Changes in Retinal Sensitivity and Anatomy Over Time.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the use of microperimetry and SS-OCT in assessing the natural changes of
      retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in
      patients with dry age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not due to safety reasons
  </why_stopped>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">May 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in retinal sensitivity in the junctional zone and in the perilesional zone of the largest atrophic loci as assessed by microperimetry for the evaluation of macular functional response at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in RPE layer thickness in the junctional zone and in the perilesional zone as measured by SS-OCT at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in photoreceptor layer thickness in the junctional zone and in the perilesional zone as measured by SS-OCT at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in retinal sensitivity in the junctional zone and in the perilesional zone of the largest atrophic loci as assessed by microperimetry at week 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in RPE layer thickness in the junctional zone and in the perilesional zone as measured by SS-OCT at week 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in photoreceptor layer thickness in the junctional zone and in the perilesional zone as measured by SS-OCT at week 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the GA area as measured by Fundus Autofluorescence (FAF) at week 12, 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA) score as assessed by Early Treatment Diabetic Retinopathy Scale (ETDRS) chart at a starting distance of 4 m at week 12, 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Luminance Visual Acuity (LLVA) score as assessed by ETDRS chart under low luminance conditions at a starting distance of 4 m at week 12, 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of scotomatous points assessed by microperimetry at week 12, 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the area of choroidal non-perfusion as measured via Optical Coherence Tomography Angiography (OCT-A) at week 12, 24 and 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostics</intervention_name>
    <description>Diagnostics</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the study

          -  Age &gt;=60 years

          -  Ability (including a sufficient general health status according to investigators
             judgement) and willingness to undertake all scheduled visits and assessments including
             predefined methodology and standards utilizing microperimetry GA secondary to AMD with
             no evidence of prior or active choroidal neovascularization (CNV) in the study eye

          -  GA lesion in the study eye must reside completely within the FAF imaging field (Field
             2- 30 degree image centered on the fovea)

          -  BCVA of 20/63 or better (Snellen equivalent) using ETDRS charts at starting distance
             of 4 m in the study eye

          -  Well demarcated area(s) of GA secondary to AMD with no evidence of prior or active CNV
             in the study eye

               -  The total GA lesion size &gt;=1.2 mm^2 (approximately &gt;=0.5 disc area [DA]) and
                  &lt;=17.78 mm^2 (approximately &lt;=7 DA) and must reside completely within the FAF
                  imaging field (Field 2-30 degree image centered on the fovea)

               -  If GA is multifocal, at least 1 focal lesion must be &gt;=1.2 mm^2 (approximately
                  &gt;=0.5 DA)

          -  Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit
             quality fundus imaging in the study eye

        Exclusion Criteria:

          -  GA in either eye due to causes other than AMD (for example, monogenetic macular
             dystrophies [e.g., Stargardt disease, cone rod dystrophy] or toxic maculopathies
             [e.g., chloroquine/hydroxychloroquine maculopathy])

          -  Receiving active treatment in any studies of investigational drugs for GA/dry AMD in
             the study eye

          -  Mean sensitivity difference &gt; 3 dB between the two microperimetry examinations in the
             screening visit.

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             AMD in the study eye

          -  Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein
             occlusion, and proliferative diabetic retinopathy in the study eye

          -  Prior treatment with Visudyne Â®, external-beam radiation therapy, or transpupillary
             thermotherapy in the study eye

          -  History of prophylactic subthreshold laser treatment for AMD in the study eye

          -  Further criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and nonâinterventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: http://trials.boehringerâingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

